
ObesityWeek 2026: Once-weekly semaglutide reduced BMI by 13.5% vs a 2.7% gain with placebo at 68 weeks in children 6 to <12 years with obesity.
With <5% of health spending going to primary care, gaps in access may worsen hospital use, burnout, and chronic disease outcomes.






